Seltorexant (JNJ-42847922) is a selective orexin-2 receptor (OX2R) antagonist being developed as a treatment for major depressive disorder (MDD). Orexins are excitatory neuropeptide transmitters ...
New findings argue against a direct causal role for dopamine during the experience of a treatment effect in the establishment of positive treatment expectations and placebo analgesia in healthy ...
Continuous positive airway pressure (CPAP) remains the cornerstone of therapy for obstructive sleep apnea, yet its impact on preventing cardiovascular disease remains uncertain. Despite widespread ...